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Abstract
Genetic variants at the 15q25 CHRNA5-CHRNA3 locus have been shown to influence lung cancer risk however there is
controversy as to whether variants have a direct carcinogenic effect on lung cancer risk or impact indirectly through smoking
behavior. We have performed a detailed analysis of the 15q25 risk variants rs12914385 and rs8042374 with smoking behavior
and lung cancer risk in 4,343 lung cancer cases and 1,479 controls from the Genetic Lung Cancer Predisposition Study
(GELCAPS). A strong association between rs12914385 and rs8042374, and lung cancer risk was shown, odds ratios (OR) were
1.44, (95% confidence interval (CI): 1.29–1.62, P=3.69610
210) and 1.35 (95% CI: 1.18–1.55, P=9.99610
26) respectively. Each
copy of risk alleles at rs12914385 and rs8042374 was associatedwith increased cigaretteconsumption of 1.0 and 0.9 cigarettes
per day (CPD) (P=5.18610
25 and P=5.65610
23). These genetically determined modest differences in smoking behavior can
be shown to be sufficient to account for the 15q25 association with lung cancer risk. To further verify the indirect effect of
15q25 on the risk, we restricted our analysis of lung cancer risk to never-smokers and conducted a meta-analysis of previously
published studies of lung cancer risk in never-smokers. Never-smoker studies published in English were ascertained from
PubMed stipulating - lung cancer, risk, genome-wide association, candidate genes. Our study and five previously published
studies provided data on 2,405 never-smoker lung cancer cases and 7,622 controls. In the pooled analysis no association has
been found between the 15q25 variation and lung cancer risk (OR=1.09, 95% CI: 0.94–1.28). This study affirms the 15q25
association with smoking and is consistent with an indirect link between genotype and lung cancer risk.
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Introduction
An association between common variants in the CHRNA5-
CHRNA3-CHRNB4 nicotinic acetylcholine receptor subunit gene
cluster on chromosome 15q25 and lung cancer risk has recently
been reported [1,2,3]; notably with the single nucleotide
polymorphism (SNP) rs1051730 and highly correlated SNPs
(including rs12914385). This association was first identified
directly through genome-wide association (GWA) studies of lung
cancer conducted by Amos et al [1] and Hung et al [2].
Concurrently with publication of these two studies Thorgeirsson
et al [3] reported a statistically significant association with the
same 15q25 variants and metrics of nicotine dependence,
concluding that this explained the elevated risk of lung cancer
they also observed. Prior to these studies the 15q25 SNP
rs16969968 which is correlated with rs1051730 was identified
through candidate gene studies as a determinant of nicotine
dependence [4]. The association between the 15q25 locus tagged
by rs16969968/rs1051730 and other correlated SNPs has been
robustly replicated for smoking related traits including, cigarettes
per day (CPD) and heavy smoking, in both candidate gene studies
[5] and recent large meta-analyses of GWA data [6,7,8].
While the lung cancer risk associated with 15q25 variants
reported in the various studies are comparable, relative risk ,1.3,
researchers differ as to whether the association is direct or simply
reflective of propensity to smoke and hence increased exposure to
tobacco carcinogens. It has been argued that the association with
CPD is not sufficient to explain the association between 15q25
variation and lung cancer risk [9], suggesting a direct role for
15q25 in lung cancer development. This possibility is supported by
the finding of an increased risk of lung cancer in both ever- and
never-smokers associated with 15q25 risk variants reported by
Hung et al [2]. The observation of higher lung cancer risks in
lower smoking-exposed strata and in individuals with a family
history of the disease has also been interpreted to implicate 15q25
variants in both smoking behaviour and directly in lung cancer
[10]. Support for this assertion comes from the finding that lung
cancer risks associated with 15q25 variants have been reported to
be essentially unchanged after adjusting for CPD [9]. Other
studies have, however failed to demonstrate a lung cancer
association in never-smokers raising doubt about a direct effect
of the 15q25 locus on disease risk [1,10,11].
Extensive genotyping of the 15q25 region has recently
provided evidence for multiple association signals defining
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a second probable disease locus independent of rs1051730–
rs16969968, which is annotatedb yt h eh i g h l yc o r r e l a t e dS N P s
rs8042374, rs6495309 and rs578776 [5,6,12].
To further explore the relationship between 15q25 variation
and lung cancer risk, specifically evidence for an indirect effect, we
have conducted a detailed analysis of the relationship between the
two 15q25 risk loci with smoking phenotype quantifying impact of
variants on lung cancer. To provide increased power to
demonstrate a relationship between 15q25 genotype and lung
cancer risk in never-smokers, we conducted a meta-analysis,
pooling our study findings with previously published data.
Materials and Methods
The flow diagram for this study and supporting PRISMA
checklist are available as supporting information; see Checklist S1
and Diagram S1.
Ethics Statement
Collection of samples and clinico-pathological information was
undertaken with informed and written consent and in accordance
with the tenets of the Declaration of Helsinki. Ethical review board
approval was obtained from the Royal Marsden NHS Hospitals
Trust and the UK Multicentre Ethics Committee.
Study participants and SNP genotyping
To evaluate 15q25 variation on the risk of lung cancer we
derived rs12914385 and rs8042374 genotypes from our previously
reported GWA study of lung cancer which annotated the two
independent loci at 15q25 [12,13]. rs12914385 is highly correlated
with both rs16969968 and rs1051730 (D’=1.0, r
2=0.81, and
D’=1.0, r
2=0.83, respectively based on HapMap CEU) thus
annotating the same locus. Comprehensive details of our GWA
study have been previously reported [12,13]. Briefly, a series of
4,343 lung cancer cases (2,782 male; mean age at diagnosis 66
years) were ascertained through the Genetic Lung Cancer
Predisposition Study (GELCAPS) [14]. All of the cases had
pathologically confirmed lung cancer. For controls we genotyped
1,479 healthy subjects (461 male; mean age at sampling 63 years)
ascertained from GELCAPS. Detailed smoking quantity data was
available on 4,019 cases and 907 controls. We defined smokers in
both cases and controls on the basis of having had a lifetime
exposure of more than 100 cigarettes. Family history of lung
cancer in cases was based on the definition of having at least one
first-degree relative affected with lung cancer. Both cases and
controls were British residents and self-reported to be of European
Ancestry. Genotyping was conducted using Illumina Human550
BeadChips and Illumina Infinium arrays according to the
manufacturer’s protocols as previously described [12,13]. To
ensure quality of genotyping, a series of duplicate samples were
included and cases and controls were genotyped in the same
batches. We have previously confirmed an absence of systematic
genetic differences between cases and controls and shown no
evidence of population stratification in these sample sets [12,13].
Statistical analysis
The risk of lung cancer associated with SNP genotype was
assessed by ORs and P-values derived from Cochran-Armitage test
using logistic regression. Deviation of the genotype frequencies in
the controls from those expected under Hardy-Weinberg Equilib-
rium (HWE) was assessed by the x
2 test. To examine the impact of
genotype on smoking behaviour, we tested trend in cigarette
consumption which has been assessed by log transformed CPD,
smoking initiation, cessation and duration using Cochran-
Armitage test. To explore the possibility that genotype influences
the age of onset of lung cancer we conducted Cochran-Armitage
test on average age of diagnosis across genotype strata in both
smokers and never-smokers. Age, sex and smoking were adjusted
in all the tests when appropriate. When adjusted for, smoking
quantity and duration were introduced using the optimal
transformation derived by Box-Cox method.
The population attributable risk (PAR), which quantifies the
proportion of the total risk of lung cancer which is due to the
genetic effect of that locus was estimated using the formulae:
PARi~
P
iPi| ORi{1 ðÞ =
P
iPi| ORi{1 ðÞ z1 ðÞ , where Pi is
the prevalence in controls of the lung cancer risk allele at the ith
locus, and ORi is the OR of the risk allele at the ith locus.
We estimated the familial relative risk of lung cancer
attributable to the smoking behaviour using previously published
methodology [15].
All the statistical analyses were undertaken in R (v2.8) software.
In all statistical analyses we considered a two-sided P-value of 0.05
or less to be statistically significant.
Meta-analysis
Study identification. To identify previously published
studies reporting the relationship between 15q25 variation and
lung cancer risk in never-smokers we interrogated the electronic
database PubMed (from January 1996 up to the end of July 2010).
The search strategy included the keywords ‘‘lung cancer, risk,
genome-wide association, candidate genes’’. We searched for any
additional studies in the bibliographies of identified publications,
including previous review articles.
Selection criteria. Studies were eligible if they were based on
unrelated individuals and examined the association between lung
cancer and polymorphic genotype at 15q25 in never smokers.
Only studies published as full-length articles or letters in peer-
reviewed journals in English were included in the analysis.
Data extraction. Data for analyses, including study design,
sample size, ethnicity, as wellas alleleand genotype frequencies, were
extracted from the published articles and summarized in a consistent
mannertoaidcomparison.Whenastudyreportedresultsondifferent
sub-populations according to ethnicity, we considered each sub-
population as a separate study in the meta-analysis.
Statistical analysis. Raw data of genotype frequencies of
15q25 variant rs16969968 and its proxies, were used for
calculation of the study-specific estimates of OR and CI. Meta-
analysis was performed under both fixed and random effects
models, estimating Cochran’s Q statistic to test for heterogeneity
and the I
2 statistic to quantify the proportion of the total variation
between studies [16,17]. To address between-study heterogeneity
we derived a pooled odds ratio under a random effects model [16].
An estimate of the potential publication bias was conducted by
examination of funnel plots. An asymmetric plot is reflective of
publication bias. The funnel plot symmetry was assessed by
Egger’s test based on inverse-variance weighted regression of the
standardized effect size (OR/standard error (SE) of OR) on their
precision (1/SE) to test whether the intercept deviates significantly
from zero. The significance of the pooled OR was determined by
the Z-test and P,0.05 was considered as statistically significant.
Results
The characteristics of lung cancer patients and control series
studied are detailed in Table 1. In keeping with the established
relationship between smoking and lung cancer risk, the lung
cancer cases reported statistically significantly higher rates of CPD
15q25 Variation and Lung Cancer Risk
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223 and P=2.00610
213, respective-
ly). Furthermore, there was however a strong trend in CPD across
age groups; cases in the uppermost quantile having a cigarette
consumption of 3.2 CPD less than those in the lowest age quantile
(P=3.01610
221).
Genotypes were obtained for .95% of cases and controls for
rs12914385 and rs8042374 (Table 2). There was no evidence of
any systematic bias in genotyping and there was a complete
concordance of SNP genotypes between duplicate samples. The
allele frequency of each SNP in controls was similar to previously
published data on the Northern European population (HapMap,
CEU population). Furthermore, there was no evidence of
population stratification as the genotype distribution in both
control series for each of the SNPs satisfied HWE.
Impact of 15q25 genotype on smoking and lung cancer
in smokers
Both SNPs showed a statistically significant association with
lung cancer risk in a strong dose-dependent fashion in smokers
(OR=1.43 and 1.32 respectively; Table 2). These associations
remained statistically significant after adjustment for age, sex and
categorized CPD (Table 2). On the basis of the risk associated with
each of the variants ,30% of the PAR of lung cancer is
underscored by the 15q25 variation in smokers.
There was a significant 1.2-fold over-representation of
rs12914385 and rs8042374 risk alleles amongst lung cancer cases
which had reported a family history of lung cancer (Table 2; P-
values for case-only analysis, 0.004 and 0.03 respectively).
We examined the relationship between genotype and smoking
behavior firstly considering CPD as a quantitative trait (Table 3).
A strong correlation between cigarette consumption and risk
genotype at both 15q25 loci was observed in cases (Table 3). While
a similar relationship between smoking and genotype was shown
in controls it was not statistically significant (Table 3). This is likely
to simply reflect small sample size and hence limited power to
demonstrate a relationship, as while we had .90% power to
demonstrate a relationship between 15q25 genotype and CPD (1
CPD per risk allele) in cases, for controls power was only ,50%
stipulating a P-value of 0.05. In cases those homozygous for
rs12914385 and rs8042374 risk alleles smoked on average 2.0–2.3
CPD more than individuals homozygous for non-risk alleles
(Table 3); the corresponding impact of rs12914385 and rs8042374
genotype on CPD in the cases was 0.9–1.0 per allele (Data not
shown). Secondly, we examined the relationship between genotype
and heavy smoking, defined as .20 CPD. In the lung cancer cases
a strong relationship between SNP risk genotype and heavy
cigarette consumption was shown (Table 4).
We determined if smoking initiation or cessation was modified
by 15q25 genotype, among ever-smokers. We observed no
statistically significant association between genotype at either
locus with smoking initiation in cases alone or controls alone or in
combined subjects among ever-smokers. Similarly we found no
evidence that genotype modified age of cessation among former-
smokers (data not shown).
We then examined the possibility that genotype might
influence age of onset of lung cancer. Armitage trend test was
used to detect trend in mean age of onset across genotype groups.
For rs12914385 risk genotype, homozygous carriers had a mean
age of diagnosis of 64.7 years compared with 65.7 and 66.4 years
in heterozygote and wild-type genotype carriers respectively
(P=0.0001). Corresponding mean ages at diagnosis by rs8042374
genotype were 65.5, 66.4 and 66.8 years, respectively (P=0.003).
These differences remained statistically significant after correc-
tion for sex and CPD and duration of smoking using linear
modeling. The median smoking duration for carriers of risk
alleles at rs12914385 or rs8042374 was 1 year higher than that of
non-carriers (44 vs 43 years and 43 vs 42 years, respectively),
albeit non-significant.
Impact of 15q25 genotype on lung cancer in never-
smokers
In never-smokers comparison of genotype frequencies in cases
and controls provided no evidence that lung cancer risk is
influenced by either rs12914385 or rs8042374 genotype (Table 2).
We examined the possibility that 15q25 genotype might influence
age of onset of lung cancer in never-smokers. For rs12914385 risk
genotype, homozygous carriers had a mean age of diagnosis of
65.8 years compared with 65.6 and 66.0 years in heterozygote and
wild-type genotype carriers respectively (P=0.99). Corresponding
mean ages at diagnosis by rs8042374 genotype were 66.8, 64.1
and 66.2 years, respectively (P=0.31).
To maximize the possibility of identifying an association
between 15q25 genotype and lung cancer in never-smokers we
conducted a meta-analysis pooling our study with previously
published case-control studies. We retrieved 95 studies using our
search criteria (Figure 1). Five of these 95 studies met our pre-
determined criteria for inclusion; two were based on Caucasians
[10,11], one on the Japanese population [18], and two reported
case-control studies from multiple countries [2,19]. The data
presented by Amos et al [1] is superseded by the current study and
was therefore not analysed. The SNPs rs16969968 and rs1051730
were each genotyped in five of the published studies and
rs8034191 in one. As rs12914385, rs1051730 and rs8034191 are
highly correlated with rs16969968 (D’=0.98–1.00 and r
2=0.81–
0.98, based on HapMap CEU) each SNP can be considered as
proxies for another. While the minor allele frequencies of
rs1051730 and rs16969968 are lower in Japanese (0.013, 0.013)
than in Caucasians (0.35, 0.35), the haplotype defined by the risk
SNP alleles is associates with lung cancer risk in the Japanese
population [18]. Given the strong correlations between SNP
Table 1. Details of the lung cancer patients and healthy
controls from GELCAPS.
Cases Control subjects
Number (Male; %) 4,343 (2,782, 64%) 1,479 (461, 31%)
Mean age (SD) years 65.4 (9.8) 63.0 (10.0)
Family history of lung cancer* 598 (14%) -
Lung cancer histology
NSCLC 3312 (76%) -
SCLC 1027 (24%) -
Other 2 (,1%) -
Smoking status
Never 241 (6%) 553 (37%)
Former 2883 (66%) 585 (40%)
Current 1219 (28%) 341 (23%)
Mean CPD (SD) 23 (19) 18 (11)
Mean pack years (SD) 45 (31) 19 (23)
*defined as having at least one first-degree relative affected with lung cancer.
NSCLC, non-small cell lung cancer;
SCLC, small cell lung cancer.
CPD, cigarettes per day.
RAF, risk allele frequency.
doi:10.1371/journal.pone.0019085.t001
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rs16969968 and rs12914385 as defining a single genetic locus
and conducted a meta-analysis of the six studies on this basis.
Collectively these five studies and our study provided data on a
total of 2,405 never-smoker lung cancer cases and 7,622 controls.
Meta-analysis of these six studies provided no evidence for a
statistically significant association between 15q25 genotype and
lung cancer risk in never-smokers; OR=1.06 (95% CI: 0.99–
1.15, P=0.12) (Figure 2). There was, however between-study
heterogeneity (Phet=0.008,I
2=68%), and the pooled OR under
a random effects model was 1.09 (95% CI: 0.94–1.28, P=0.26).
Between-study heterogeneity was largely attributable to inclusion
of the Japanese study. Omitting this study from the analysis
between-study heterogeneity was non-significant but the associ-
ation remained non-significant with a pooled OR of 1.05 (95%
CI: 0.97–1.13, P=0.20; Phet=0.06, I
2=56%). No publication
bias was found by examining either the funnel plot or formal
Egger’s test (P=0.34).
Discussion
While an association between 15q25 variation and lung cancer
risk is now well established there is currently no consensus on the
relative impact of variants on propensity to smoke versus a direct
carcinogenic effect. In this study we have conducted a detailed
analysis of 15q25 variants, smoking behaviour and lung cancer risk
Table 2. Risk estimates for rs12914385 and rs8042374 stratified by selected variables.
Lung cancer
cases Control subjects Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
rs12914385 n( % ) n( % )
Smokers
1
CC 1230 (30.6) 373 (41.1) 1.00 (Ref)
TC 1973 (49.1) 413 (45.5) 1.45 (1.24–1.70) 3.74610
206 1.47 (1.25–1.73) 4.08610
206
TT
{ 815 (20.3) 121 (13.3) 2.04 (1.63–2.55) 3.67610
210 2.00 (1.59–2.52) 3.99610
209
RAF, per allele OR 0.45 0.36 1.43 (1.29–1.59) 2.10610
211 1.43 (1.28–1.59) 1.79610
210
Familial cases
¥
CC 154 (26.3) 373 (41.1) 1.00 (Ref)
TC 292 (49.9) 413 (45.5) 1.71 (1.35–2.18) 1.14610
205 1.71 (1.33–2.19) 2.30610
205
TT
{ 139 (23.8) 121 (13.3) 2.78 (2.05–3.78) 7.03610
211 2.81 (2.04–3.87) 2.76610
210
RAF, per allele OR 0.49 0.36 1.67 (1.44–1.95) 2.37610
211 1.68 (1.44–1.96) 9.41610
211
Never-smokers
CC 100 (41.8) 217(39.2) 1.00 (Ref) 1.00 (Ref)
TC 109 (45.6) 260 (47.0) 0.91 (0.66–1.26) 0.57 0.90 (0.64–1.27) 0.56
TT
{ 30 (12.6) 76 (13.7) 0.86 (0.53–1.39) 0.53 0.81 (0.49–1.34) 0.41
RAF, per allele OR 0.35 0.37 1.09 (0.87–1.36) 0.47 1.10 (0.87–1.39) 0.43
rs8042374
Smokers1
AA
{ 2668 (66.5) 541 (59.6) 1.00 (Ref)
AG 1207 (30.1) 314 (34.6) 0.78 (0.67–0.91) 1.60610
203 0.78 (0.66–0.92) 2.51610
203
GG 136 (3.4) 52 (5.7) 0.53 (0.38–0.74) 1.86610
204 0.52 (0.37–0.73) 2.01610
204
RAF, per allele OR 0.82 0.77 1.32 (1.17–1.50) 8.19610
206 1.33 (1.17–1.51) 1.44610
205
Familial cases
¥
AA
{ 413 (70.7) 541 (59.6) 1.00 (Ref)
AG 155 (26.5) 314 (34.6) 0.65 (0.51–0.81) 2.18610
204 0.63 (0.50–0.80) 1.84610
204
GG 16 (2.7) 52 (5.7) 0.40 (0.23–0.72) 1.95610
203 0.41 (0.23–0.74) 3.05610
203
RAF, per allele OR 0.84 0.77 1.56 (1.29–1.88) 5.05610
206 1.57 (1.29–1.92) 7.21610
206
Never-smokers
AA
{ 135 (56.5) 314 (56.8) 1.00 (Ref) 1.00 (Ref)
AG 86 (35.98) 206 (37.3) 0.97 (0.70–1.34) 0.86 1.01 (0.73–1.41) 0.94
GG 18 (7.5) 33 (6.0) 1.27 (0.69–2.33) 0.44 1.37 (0.73–2.59) 0.33
RAF, per allele OR 0.75 0.75 1.05 (0.82–1.34) 0.7 1.10 (0.85–1.42) 0.47
RAF, risk allele frequency.
RAF of rs12914385 and rs8042374 in the 1958 Birth Cohort 0.39 and 0.76 respectively.
1Current and former smokers combined.
{Risk genotype.
¥excludes 6 of the never-smoker cases which reported a family history of lung cancer.
Adjusted for age, sex and categorized smoking quantity CPD (0–10; 11–20; 21–30; 31+).
doi:10.1371/journal.pone.0019085.t002
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into the underlying basis of this cancer association.
We confirm previous observations of a strong relationship
between the two 15q25 loci annotated by rs12914385 and
rs8042374 with both smoking behaviour and risk of lung cancer.
We found that for each locus smokers carrying two copies of the
risk allele smoked on average two more CPD than those
homozygous for non-risk alleles.
Much of the assertion that 15q25 variation has a direct effect on
lung cancer risk rather than solely being a proxy for smoking
comes from the observation that the lung cancer association is not
accounted for by the relationship with smoking quantity. Applying
the Doll and Peto model [20] of the dose-response relationship
between smoking and lung cancer for those aged 16–25 smoking
,40 CPD, Brennan and co-workers estimated that a 1.2
difference in CPD between rs16969968 homozygotes only results
in a 9% increase in lung cancer risk [9]. This is substantially lower
than the observed association between rs16969968 and lung
cancer risk. While we found that adjustment for CPD had little
effect on the estimation of lung cancer risk associated with 15q25
variants, it has consistently been shown that for both men and
women the number of years of cigarette smoking is far more
important than CPD in predicting lung cancer risk [20,21]. In the
Peto and Doll model the risk of lung cancer for men aged 40–79
years is proportional to (CPD+6)
2.(age-22.5)
4.5 [20]. Under this
model even a 1.0 CPD difference will account for the observed
difference in lung cancer risk if genotype influences the duration of
smoking by 1 year over a 30 year period. It has been previously
shown that CHRNA3-CHRNA5 variants influence early tobacco
addiction [22] and recent studies have demonstrated that 15q25
genotype influences the ability to stop smoking [23]. Hence it is
likely that carriers of 15q25 risk genotypes will smoke more
consistently over a longer period and have more sustained smoking
behaviour. Although we found no strong relationship between
duration of smoking and genotype in lung cancer cases our study
findings are concordant with this hypothesis.
An over-representation of 15q25 risk alleles in familial lung
cancer cases and association with early-onset disease has been
suggested to provide evidence for a direct effect of variants on lung
cancer risk. It is, however well established that smoking behaviour
has a high heritability (0.5–0.7) [24]. Since the relative risk of lung
cancer associated with smoking is ,30 [25] the familial lung
cancer risk directly attributable to inherited propensity to smoke is
,1.4 if 10%–25% of the population consistently smoke. As with
the 15q25 locus any over-representation of variants in familial or
early-onset lung cancer can readily be accounted for through an
indirect mechanism. It is noteworthy in this respect that while
15q25 risk variants were associated with early-onset disease in
smokers no such association was seen in never-smoker lung cancer
cases. Moreover given that the familial relative risk of lung cancer
is ,1.7 [26], genetically determined smoking behaviour is likely to
contribute significantly to the observed clustering of lung cancer.
The design of our study is very similar to the other case-control
studies which have previously investigated the relationship
between polymorphic variation and lung cancer risk. While data
on lung cancer diagnoses are derived from histological records,
details on smoking behaviour was obtained through self-admin-
istered questionnaires; thus there is a qualitative difference in the
robustness of these two endpoints used in our analysis. Self-
reported data about smoking behaviours several decades ago is
inherently problematic. Cigarette use has been shown to be
commonly under-reported by smokers in studies which have
correlated self-reported cigarette use with cotinine levels [27]. If
underreporting smoking habit or cigarette consumption differs
between cases and controls this is a potential source of significant
bias in establishing a direct association between the 15q25 locus
and lung cancer risk. This is especially of concern as 15q25
genotype influences smoking behaviour. Beside these issues it has
been shown that carriers of risk variants extract a greater
carcinogenic nitrosamine per cigarette dose [28]. While self-
reported CPD has enabled an association between 15q25 and
smoking to be demonstrated, even if accurately assessed CPD does
not adequately take into account carcinogenic load. In view of this,
simple adjustments using self-reported CPD metrics is likely to be
suboptimal for teasing out direct effects on lung cancer risk and it
is perhaps not surprising that effect sizes for many 15q25 lung
cancer associations appear relatively unchanged when simple
adjustments are made. Future epidemiological studies seeking to
demonstrate a direct effect of 15q25 on lung cancer risk should
take into consideration the significant potential issue of confound-
ing in study design.
The strongest epidemiological data supporting a direct role of
genetic variation at 15q25 as a risk factor for lung cancer would be
provided by demonstration of an association in never-smokers.
While our own study of never-smokers was relatively small it had
,80% power to demonstrate a lung cancer association assuming
Table 3. Smoking intensity and dependence by 15q25
genotype.
Lung cancer cases Control subjects
Genotype n Mean CPD P-value* n Mean CPD P-value*
rs12914385
CC 1230 21.6 373 18.1
TC 1973 22.2 413 18.5
TT
{ 815 23.9 121 18.5
4.76610
205 0.38
rs8042374
AA
{ 2668 22.7 541 18.6
AG 1207 21.8 314 18.0
GG 136 20.7 52 17.9
7.55610
203 0.48
*From Kruskal-Wallis test.
{Risk genotype.
doi:10.1371/journal.pone.0019085.t003
Table 4. Prevalence of rs12914385 and rs8042374 risk alleles
in light and heavy smoking lung cancer cases and controls.
Lung cancer cases Control subjects
Genotype CPD n RAF P-value* n RAF P-value*
rs12914385
1–20 2611 0.43 688 0.36
21+ 1407 0.47 5.65610
204 219 0.37 0.58
rs8042374
1–20 2606 0.81 688 0.76
21+ 1405 0.83 3.72610
203 219 0.79 0.37
*P values calculated using the Cochran-Armitage test.
RAF, risk allele frequency.
doi:10.1371/journal.pone.0019085.t004
15q25 Variation and Lung Cancer Risk
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19085an OR of 1.3. While this effect size is comparable to that seen for
the lung cancer association in smokers it can be asserted that any
direct association may be more modest. However, the meta-
analysis we conducted failed to demonstrate a significant
relationship despite having in excess of 80% power to show a
relative risk of 1.1. Hence if there is a direct effect of 15q25 on
lung cancer risk it is likely to be overshadowed by the indirect
effect.
Although our data thus favours an indirect effect of 15q25
variation on lung cancer risk we cannot entirely exclude the
possibility of direct effect. The acid test proving a direct effect is
likely to be reliant on biological assays. Evidence that nicotine is
either carcinogenic or co-carcinogenic or functions as a tumour
promoter for lung cancer would support the plausibility of a direct
relationship between the 15q25 locus and lung cancer risk. There
is evidence that variants in the region are associated with
decreased expression of CHRNA5 in the lungs and that CHRNA5
expression is higher in lung cancers favouring a direct role [29].
While the SNP rs16969968 is a non-synonymous SNP causing the
D398N substitution in CHRNA5 and while 398N causes decreased
response to a nicotine agonist [30], a direct role of this variant in
lung cancer biology has thus far not been shown. Moreover to date
data on the direct effect of nicotine on lung cancer biology is
sparse and inconsistent (reviewed in [31]).
In conclusion the results of our analyses reaffirm the strong
relationship between the 15q25 locus and both smoking and lung
cancer risk. However, our findings do not provide evidence for
direct effect of 15q25 on lung cancer risk and it is possible to
explain this association in smokers through the influence on
smoking behaviour. Assertion of a direct effect of variants on lung
cancer risk is currently weak and this should not detract from
concerted efforts to reduce lung cancer burden through public
Figure 1. Inclusion and exclusion criteria for studies.
doi:10.1371/journal.pone.0019085.g001
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influences smoking behaviour it is possible that assaying 15q25
genotype may have healthcare utility in helping the tailoring of
smoking cessation strategies.
URLs
The R suite can be found at http://www.r-project.org/
HAPMAP: http://www.hapmap.org/
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